Clinical trials enable us to answer questions about what is the role of this new technology in improving patient care.
Peter Mac has been involved in trials of theranostics for more than 20 years and has led pivotal trials in prostate theranostics since 2015. ProsTIC has been established to accelerate our research and expand our portfolio of clinical trials.
If you are a patient and interested in participating in a clinical trial, you should contact your medical specialist who can advise whether you might be suitable for a clinical trial and organise appropriate referrals.
A selection of clinical trials currently recruiting at Peter Mac including the following:
AlphaBet is recruiting 36 men with Metastatic Castration-Resistant Prostate Cancer over 24 months for a prospective, single-centre, single-arm phase I/II trial. The study aims to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of Radium-223 (223Ra) in combination with lutetium-177-prostate-specific membrane antigen-Imaging & Therapy (177Lu-PSMA-I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC).
In phase II, AlphaBet aims to determine treatment efficacy (Prostate-Specific Antigen-Response Rate [PSA-RR]).
This study is currently open for recruitment.
VIOLET is recruiting 30 men for a prospective, single-centre, single-arm phase I/II trial.
Phase I aims to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of [161Tb]Tb -PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Phase II aims to evaluate the safety of [161Tb]Tb -PSMA-I&T in patients with mCRPC.
This study is currently open for recruitment.
LuCAB is a prospective, single-centre, single-arm, phase I/II trial recruiting 38 men over 18 months to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of cabazitaxel in combination with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).
This study is now open for recruitment.
This is a prospective multicentred, randomized, phase III trial which will evaluate the addition of PSMA PET as non‐inferior to standard of care (SOC) & to detect clinically significant prostate cancer (sPCa) while providing the advantages of (1) reducing unnecessary biopsies and (2) limiting to targeted‐only biopsies in men with clinical risk of prostate cancer (PCa) and negative or equivocal MRI. 660 men will be enrolled in this trial (330 in experimental arm, 330 in control arm) from 5+ sites over a recruiting period of 3 years with a potential 2 years follow-up for participants.
Currently open for recruitment.
This phase 1 study examines the use of Lu-PSMA in combination with a PARP inhibitor (olaparib) in men with castration-resistant metastatic prostate cancer who have progressed on prior novel androgen-receptor targeted agents (enzalutamide, abiraterone and/or apalutamide). Radiation therapy kills cancer cells by damaging DNA. PARP-inhibitors are therapies that kill cancer cells by preventing their ability to repair damaged DNA. In this study we will examine whether PARP-inhibitors may synergize with radiation therapy in killing cancer cells by preventing DNA repair after radiation-induced DNA damage.
This phase 2 randomised study is currently recruiting 140 men with newly diagnosed metastatic prostate cancer at 11 Australian studies. Men must have “high volume” disease defined on a PSMA PET/CT scan. Men will be randomised to the experimental arm (Lu-PSMA followed by docetaxel chemotherapy) or standard-of-care (docetaxel). All men with receive androgen deprivation therapy (ADT).
Open for recruitment.
This is an open label, randomised, stratified, 2-arm, multicentre phase 2 clinical trial recruiting 160 participants over 12 months and followed until 150 events occurred (approximately another 18 months). Participants will be randomised to enzalutamide or enzalutamide and Lu-PSMA in a 1:1 ratio. A minimisation approach will be used to minimise chance imbalances across the following stratification factors: study site, volume of disease (>20 versus ≤20 sites of disease measured on 68Ga-PSMA PET/CT), prior treatment with early docetaxel for castration- sensitive disease (yes vs no), and prior treatment with early abiraterone for castration-sensitive disease (yes vs no).
This study is open for recruitment
This phase II study is to investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC). This is an open label, randomised, stratified, multicentre phase 2 clinical trial recruiting 110 participants over 18 months and followed for 12 months.
Recruitment is currently open.
POPSTAR II will be investigating focal targeted radiotherapy alone or combined with 2 cycles of targeted radionuclide therapy in men with limited sites of metastatic prostate cancer. This is an open label, randomised, non-comparative, stratified phase II clinical trial recruiting 92 patients. Patients with oligometastatic prostate cancer will be randomised in a 1:1 ratio to either stereotactic ablative body radiotherapy (SABR) alone or SABR plus 2 cycles of Lu-PSMA. This study is expected to open for recruitment in early 2023.
In this study, 20 men with newly diagnosed prostate cancer and high-risk features scheduled to undergo prostatectomy will have 1 or 2 cycles of Lu-PSMA prior to surgery. After each cycle of Lu-PSMA, imaging will be performed to assess how much radiation was delivered to prostate cancer. We will also assess the biochemical, imaging and pathology response to Lu-PSMA.
This study is fully recruited.
This trial examines the use of Lu-PSMA in combination with immunotherapy (pembrolizumab) in men with castration-resistant metastatic prostate cancer who have progressed on prior enzalutamide, abiraterone and/or apalutamide. If suitable, men in this trial will be treated with up to 6 cycles of Lu-PSMA and pembrolizumab for up to 35 cycles.
This study is now closed for recruitment.